The Traderszone Network

Published in TZ Latest News 8 September, 2017 by The TZ Newswire Staff

Here’s Why United Therapeutics Sank as Much as 10.8% Today

Shares of rare-disease specialist United Therapeutics (NASDAQ: UTHR) dropped nearly 11% today after the company announced that a phase 3 trial evaluating Orenitram in patients with pulmonary arterial hypertension, or PAH, will continue through completion after an independent interim analysis was conducted. That may sound like an odd reason to send shares lower, but investors were hoping that the trial would be stopped early had the drug shown overwhelming efficacy. 

read more